Avoid Holiday Weight Gain with Expert Tips 10.4.12 — (HealthNewsDigest.com) With fall upon us, it’s difficult not to think of holidays, parties, and fun. However, for those who are dieting, this time of year can be particularly challenging. Below, Manhattan Medical Weight Loss Physician Dr. Sue DeCotiis provides general weight loss tips and Co-Founder of […]
Glamour Magazine Consults with Dr. Decotiis
New York physician and skincare specialist Dr. Sue Decotiis was recently consulted by Fiorella Valdesolo of Glamour Magazine for some advice for getting some extra desirable décolleté. “The skin of the décolletage is thinner since there is not as much collagen,” Dr. Decotiis explains. “It is an area that is neglected as it often does […]
When a Facial Isn’t Enough
Today, more people than ever are opting to take a medical approach to skin care. Many skin problems come from within – and need to be addressed from within — although they may exhibit a “cosmetic” downside such as dryness, wrinkling and discoloration. Aesthetic medical technology (aka the “Medispa“) is growing at an explosive rate: […]
Dr Decotiis Discusses Weight Loss Pill Qsymia on FoxNews.com
Weight Loss Pill Qsymia Now for Sale 9.18.12 – FoxNews.com The weight loss pill Qsymia is now for sale from online pharmacies. Qsymia — pronounced kyoo-SIM-ee-uh, according to Vivus Pharmaceuticals — is the first new weight loss drug to reach market in 13 years. Vivus chose the name Qsymia after the FDA rejected a previous name, […]
Dr. Decotiis Interviewed by Web MD regarding Qsymia Weight Loss Pill
It’s an important day for people whose weight is destroying their health. The prescription weight loss pill Qsymia is now for sale from certified pharmacies. For weight loss specialists, any new tool we can get our hands on is very exciting. We’re not talking about the person who just needs to lose 10 pounds. […]
Dr Sue Decotiis Contributes to French Tribune Report on Qsymia
Vivus Expectations Drop Its Shares 10.15.12 FrenchTribune.com Vivus Inc.’s (US: vvus) expectations on Friday suddenly let it shares down by 12%, a recent report has uncovered. It had expressed estimations that European regulators might recommend that its Qsymia drug should not be approved by the US Food and Drug Administration. However, shares of other firms either manufacturing […]
